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The avermectins and milbemycins contain a commonmacrocyclic lactone (ML) ring, but are fermentation
products of different organisms. The principal structural difference is that avermectins have sugar groups
at C13 of the macrocyclic ring, whereas the milbemycins are protonated at C13. Moxidectin (MOX),
belonging to the milbemycin family, has other differences, including a methoxime at C23. The avermec-
tins and MOX have broad-spectrum activity against nematodes and arthropods. They have similar but not
identical, spectral ranges of activity and some avermectins and MOX have diverse formulations for great
user ﬂexibility. The longer half-life of MOX and its safety proﬁle, allow MOX to be used in long-acting for-
mulations. Some important differences between MOX and avermectins in interaction with various inver-
tebrate ligand-gated ion channels are known and could be the basis of different efﬁcacy and safety
proﬁles. Modelling of IVM interaction with glutamate-gated ion channels suggest different interactions
will occur with MOX. Similarly, profound differences between MOX and the avermectins are seen in
interactions with ABC transporters in mammals and nematodes. These differences are important for
pharmacokinetics, toxicity in animals with defective transporter expression, and probable mechanisms
of resistance. Resistance to the avermectins has become widespread in parasites of some hosts and
MOX resistance also exists and is increasing. There is some degree of cross-resistance between the aver-
mectins and MOX, but avermectin resistance and MOX resistance are not identical. In many cases when
resistance to avermectins is noticed, MOX produces a higher efﬁcacy and quite often is fully effective at
recommended dose rates. These similarities and differences should be appreciated for optimal decisions
about parasite control, delaying, managing or reversing resistances, and also for appropriate anthelmintic
combination.
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The anthelmintic macrocyclic lactones (MLs) endectocides are
the cornerstone of modern parasite control. They belong to a large
family of hydrophobic, structurally related compounds widely
used in animals and humans and also for pest control on crops.
This review will focus on the comparison of moxidectin (MOX), a
member of the milbemycin subfamily of MLs, and the avermectin
subfamily of MLs used in animals and humans. Since their develop-
ment in the early 1980s, the success of the MLs has relied on their
remarkable broad-spectrum activity, safety proﬁle and ease of
administration (McKellar and Benchaoui, 1996; Molyneux et al.,
2003; Kita et al., 2007). Furthermore, the MLs are effective against
benzimidazole-, levamisole- and pyrantel-resistant strains of nem-
atodes, whose emergence severely restricted the ﬁght against par-
asites in the late 1970s (McKellar and Scott, 1990). The
avermectins are derived from a soil bacterium Streptomyces aver-
mitilis, selected on the basis of insecticidal and anthelmintic activ-
ity. Ivermectin (IVM) and abamectin (ABM) were the ﬁrst MLs
developed in the early 1980s for use in animals and IVM, in partic-
ular, revolutionized parasite control in production animals, heart-
worm disease prevention in companion animals and antiﬁlarial
treatment in humans. Subsequently, a number of avermectins,
including doramectin (DRM), eprinomectin (EPM) and selamectin
(SLM) were developed. The other subfamily of MLs, called milbe-
mycins, was isolated, before the avermectins, initially from fer-
mentation of a distinct soil bacterium, Streptomyces hygroscopicus
in 1967 and subsequently from Streptomyces cyaneogriseus in
1983. MOX was derived from the latter, as nemadectin (F-
29249a), chemically modiﬁed and subsequently commercialised.
The avermectins and milbemycins, also referred to as endectocides
because of their activity against endoparasites and ectoparasites,
received considerable interest in the agricultural chemical industry
because of their extremely high activity against arachnoid and
nematode pests, low toxicity to mammals, generally benign envi-
ronmental characteristics, and unique mode of action.
The milbemycins and avermectins have a common pharmaco-
phore: the 16-member macrocyclic lactone ring fused with both
benzofurane and spiroketal functions in a three-dimensional
arrangement, which is recognised by speciﬁc chloride ion channelreceptors. The high afﬁnity binding of IVM and other MLs to these
receptors is responsible for the mode of action of this class of
drugs. However, they also display structural differences related
to the presence or absence of several substituents. Although it
has been claimed that these drugs have identical modes of action,
many differences in terms of pharmacokinetics, pharmacodynam-
ics and toxicity have been reported between MOX and the aver-
mectins. Because MLs have systemic actions and must cross the
tissues of the host organism before reaching the target parasite,
the drug disposition in the host, e.g., concentration and half-life,
are determinant for drug efﬁcacy and utility. Thus, any factor that
modulates the amount of active drug that reaches the target and
the duration of its effects is important. The physicochemical prop-
erties modulate the rate of exchange between the tissues and the
blood stream. MLs are metabolized, to a small and variable extent,
both in the host (Chiu et al., 1987; Alvinerie et al., 2001) and nem-
atode parasites (Alvinerie et al., 2001). Biotransformation plays
only a minor role in the in vivo elimination of MLs. Rather, the abil-
ity of MLs to be actively transported by efﬂux proteins present in
mammalian and parasite cell membranes is a major pathway for
drug elimination (Lespine et al., 2008). Molecular studies indicate
that these drugs interact strongly not only with ligand-gated ion
channels, the mode-of action receptors of nematodes and arthro-
pods, but also with efﬂux ABC transporters. Mammalian efﬂux
ABC transporters are involved in the efﬂux of a broad range of
xenobiotics and play a major role in the toxico- and pharmacoki-
netics of MLs in the host. These interactions clearly differ between
MOX and avermectins and the interaction of MOX with mamma-
lian P-gp is much weaker compared with IVM (Lespine et al.,
2006). Furthermore, the overexpression of these multidrug ABC
transporters, such as P-glycoprotein (P-gp) and multidrug-resis-
tance associated protein (MRPs), appears to be part of the mecha-
nism of IVM resistance in nematodes. MOX has markedly different
and reduced effects on causing overexpression of both P-gps and
MRPs in nematodes (Prichard and Roulet, 2007; Ardelli and Prich-
ard, 2008). These differences suggest different pathways for the
control of MOX disposition and resistance selection, compared
with IVM, and may also be the basis for different toxicity. Research
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Fig. 1. Schematic ﬁliations of macrocyclic lactones: from the soil bacteria to the therapeutic products.
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ences in some depth so that optimal use can be made of the dif-
ferent MLs. We will consider the similarities and differences
between avermectins and MOX in their chemistry, formulation
and use, spectrum of activity, pharmacodynamics, pharmacoki-
netics, resistance and safety. Differences in the substituents and
physicochemical properties may impact on efﬁcacy, resistance
selection, safety and ﬂexibility in formulation and use. Where
possible we attempt to explain the differences observed in these
properties by the inferred molecular interactions with the recep-
tors of interest.2. Chemistry and physico-chemical properties
2.1. Avermectins
Avermectin are members of a group of pentacyclic 16-mem-
bered lactone compounds with endectocide activity (Campbell,
1989). Abamectin (ABM) ﬁrst arose from the isolation, in the labo-
ratories of the Kitasato Institute, of a soil-dwelling bacterium, S.
avermitilis, and its transmittal in 1974 to the laboratories of Merck
& Co., Inc. where its activities against nematodes and many ecto-
parasites were discovered (Stapley and Woodruff, 1982). ABM is
the mixture of avermectin B1a (>90%) and avermectin B1b (<10%).
A-series compounds are methoxylated at the 5-position, whereas
the B-series have an underivatized hydroxyl group at that position.
The 1-subset compounds have an oleﬁnic bond between C22 and
C23; the 2-subset compounds possess a hydroxyl group at position
23 due to the hydration of the double bonds (see Supplementary
Fig. S1). They are considered to have very similar biological activ-
ities and toxicological properties. Overall avermectins are charac-
terised among other MLs by the presence of a sugar substituent
on the 13-position and of secondary butyl or isopropyl in the 25-
position.
Ivermectin (IVM), the most commonly used avermectin, is a
chemically reduced 22,23-dihydro derivative of ABM, and is a mix-
ture of 22,23-dihydroavermectin B1a (>90%) and 22,23-dihydro-
avermectin B1b (<10%), differing from the components of
abamectin by a single methylene group at the 26 position (Camp-
bell, 1989). The ﬁliations between the major MLs are shown in
Fig. 1.
Eprinomectin (EPM) is the amino-avermectin derived from
avermectin B1 with modiﬁed terminal oleandrose moiety called
400-epiacetylamino-400-deoxy-avermectin B1. It was found, from
IVM analogues synthesised by Merck, to have a favourable milk
residue proﬁle (Shoop et al., 1996).
Doramectin (DRM) is prepared by mutational biosynthesis and
it has a closer structural similarity to ABM than to IVM (Goudieet al., 1993). There is a different substituent at the 25 position
without the dihydro modiﬁcation at the 22–23 position. It differs
from IVM by having a cyclohexyl group in the C25 position of
the avermectin ring. Selamectin (SLM) is a semisynthetic monosac-
charide oxime derivative of DRM. This drug has been selected for
its efﬁcacy against heartworms and for providing utility against
ﬂeas at a dose that is safe for use in dogs and cats (Banks et al.,
2000). In terms of chemical structure and because of its monosac-
charide, it is an interesting intermediate between the disaccharide
avermectins and milbemycins.2.2. Moxidectin and other milbemycins
A fermentation product with very high acaricide activity was
isolated in 1967 from S. hygroscopicus. In 1972, the 16-membered
macrocyclic lactones structure of the active compound was eluci-
dated and identiﬁed as milbemycin and from this ﬁrst discovery,
the anthelmintic milbemycin oxime (MO) was derived (Takiguchi
et al., 1983). Subsequently, an active fermentation milbemycin
product nemadectin was isolated from S. cyaneogriseus in 1983
and moxidectin (MOX) was later chemically derived from this
compound by the addition of a methoxime moiety at C-23 (Fig. 1).
Chemically, when compared to avermectins, milbemycins are
unglycosylated, lacking a bisoleandrosyl moiety in the 13-position
(Supplementary Fig. S1). The milbemycins not only differ from the
avermectins in lacking sugar groups at position-13, they also differ
from the avermectin aglycones by being protonated at this position
in contrast to the avermectin aglycones which are hydroxylated at
this position. They also have an ethyl or a methyl at the 25-posi-
tion. They can differ from one to another milbemycin by their sub-
stituant in the 5- and 25-position. MOX has a substituted oleﬁnic
side chain at the 25-position and methoxime moity at the 23-posi-
tion which are both characteristics speciﬁc to this drug and not
found in other commercial milbemycins or avermectins.3. Formulations and mode of use
Because most of the avermectins are used at relatively low dose
rates, have high lipophilicity, stability and safety, there is a great
degree of ﬂexibility in their formulation. For example, IVM is for-
mulated as a tablet for human use (Mectizan) or as chewables
for dogs (e.g., Heartgard); as an oral liquid for humans (Stromec-
tol) and drench for small ruminants (e.g., Ivomec Drench);
injectable (e.g., Ivomec Injection for cattle and pigs), including
long-acting injectable formulations in some markets (e.g., Ivomec
Gold), pour-on (Ivomec Pour-on), and long-acting boluses in
some markets for cattle; and pastes for horses (e.g., Eqvalan).
There are many other formulations for the various avermectins,
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other pharmacologically active ingredient to broaden the spectrum
of action.
MOX is similarly a very versatile, stable and safe molecule. Be-
cause of its exceptionally high potency and safety, it is used in dose
rates varying between 3 lg/kg (e.g., ProHeart for dogs) to 2.5 mg/
kg (e.g., Advantage Multi for dogs) and comes in tablets (e.g.,
ProHeart), oral drench for sheep, oral gel/paste for horses (e.g.,
Quest), injectable (e.g., Cydectin) and pour-on (e.g., Cydectin
Pour-on) for cattle, and topical solution for dogs and cats (e.g.,
Advocate, Advantage Multi). Because of its remarkable potency
against nematodes and long half-life due to its lipophilicity, low
susceptibility to transport by ABC transporters (see discussion be-
low) and in vivo stability, MOX is particularly suitable for long-act-
ing formulations ranging from Cydectin LA, given as an injection
at 1 mg/kg for cattle which has activity for up to 150 days, and Pro-
Heart6 providing dogs with heartworm disease prevention for
6 months, and in some countries, ProHeart12 which provides
dogs with protection against heartworm disease for 1 year.
This is a far from exhaustive list of formulations and modes of
administration for these remarkable pharmaceuticals. While the
avermectins and MOX show many similarities in their ability to
be formulated and are used in a variety of ways, the characteristics
and use are not identical in all respects; most notably in the ability
of MOX to maintain activity over very long period of time in differ-
ent long-acting formulations. In addition to the inherent half-life of
the ML, the vehicle also plays an important role in achieving a long
period of activity.4. Spectrum of activity
The activity of the avermectins and MOX against nematode and
ectoparasites of veterinary importance has been comprehensively
reviewed in Vercruysse and Rew (2002), and in this review section
only differences between the MLs or between formulations will be
discussed.4.1. Cattle
IVM, ABM, DRM, EPM and MOX are all used to control gastroin-
testinal and lung nematodes and ectoparasites of cattle. Subcuta-
neous injection is the most efﬁcient route for ML administration
in terms of drug bioavailability in cattle and other species, when
compared to oral and topical administration (Gayrard et al.,
1999; Laffont et al., 2001; Lespine et al., 2003). The usual dose rate
for all of the MLs in cattle is 0.2 mg/kg for injectable and 0.5 mg/kg
for pour-on formulations. The higher dose rate for pour-on formu-
lations reﬂects the fact that the active ingredient is less well ab-
sorbed through the skin than from the injection site or the
gastrointestinal tract. However, cattle will lick each other after
pour-on application of anthelmintic and a variable portion of the
pour-on dose may be orally ingested, and will lead to unexpected
levels of drug in the organisms and efﬁcacy (Bousquet-Melou
et al., 2011). It is well known that IVM and MOX have different
plasma and tissue kinetics (see paragraph 6.1) which affect the
duration of activity. For a given method of administration, the
avermectins have activity for 14–28 days, while MOX has the lon-
gest period of activity (from 14 to 42 days, depending on the target
species) when given as a single dose (non long-acting formulation).
This is in accordance with the longer persitance of MOX efﬁcacy in
the host organism. Generally, IVM and MOX should not be used in
dairy cattle that are producing milk for human consumption, un-
less milk withholding periods are observed. Because very little is
excreted in the milk, EPM was developed for dairy animals (see
discussion below). However, in some jurisdictions, MOX pour-onis registered for use in lactating dairy cattle with a zero milk with-
drawal, based on the lower toxicity of MOX compared with IVM.
Route of administration affects, to some extent, the efﬁcacy of
MLs against ectoparasites. For example oral administration is less
effective than injectable or pour-on administration against mange
mites (Benz et al., 1989), and injection may be less efﬁcacious than
pour-on administration against some biting lice, such as Bovicola
bovis (Chick et al., 1993). As single therapeutic (not long-acting)
treatment, the MLs have variable activity against the single host
tick, Rhipicephalus (Boophilus) microplus, with IVM pour-on
(0.5 mg/kg) or injectable (0.2 mg/kg) showing 50% and 80% efﬁ-
cacy, respectively (Cramer et al., 1988). Higher and more persistent
activity (up to 28 days) was achieved with DRM (Muniz et al.,
1995) and MOX (up to 21 days) (Guglielmone et al., 2000). The
MOX long-acting injectable formulation (Cydectin LA, at 1 mg/
kg) was found to provide 50 days of protection against B. microplus
(Davey et al., 2011).
4.2. Sheep and goats
Registration of different ML formulations for sheep and goats
varies in different jurisdictions and largely reﬂects economic fac-
tors. In general, oral administration is preferred for small rumi-
nants. Although there are few jurisdictions where EPM has been
registered for use in small dairy ruminants, the cattle formulations
are sometimes used because of low residues in milk. All of the MLs
show high efﬁcacy against nematode endoparasites and some ecto-
parasites of small ruminants, provided resistance has not devel-
oped. Unfortunately, resistance to the avermectins has become
widespread in nematode parasites of small ruminants. Usually
when avermectin resistance ﬁrst develops, it affects the efﬁcacy
of all of the avermectins. However, MOX is usually still highly
effective at its recommended dose rate against the avermectin-
resistant parasites (see below). However, MOX resistance can occur
with ongoing selection pressure from MOX use.
4.3. Equines
IVM (Eqvalan and other proprietary names) and MOX (Quest
and other proprietary names) are registered for use in horses. They
are usually given orally as a paste, although a liquid oral formula-
tion of IVM for horses is also available. IVM and MOX are highly
effective against most of the important nematode parasites of
horses as well as bots. They show a very similar spectrum, except
that MOX is more efﬁcacious against encysted small strongyle lar-
vae. As small strongyles are considered one of the most pathogenic
worm parasites of horses, removal of encysted larvae can be
advantageous. With other equine anthelmintics, adult small stron-
gyles, which have been removed by treatment, may be rapidly re-
placed from developing larval stages which remain in the equine
after treatment. Removal of the encysted larval stages by MOX
means that new infective larvae must be ingested and develop to
adults before the risk of morbidity from small strongyles can be-
come important again.
4.4. Dogs and cats
The avermectins (IVM and SLM) and the milbemycins (MO and
MOX) are used for heartworm disease prevention in dogs and cats.
SLM, MO and the Advantage Multi (or Advocate) formulation of
MOX also have activity against immature and adult stages of
roundworms and hookworms in dogs and cats, whipworms and
lungworms of dogs, ear mites (Otodectes cynotis), sarcoptic mange
mites and demodex mites. Advantage Multi (Advocate) contains
imidacloprid in combination with MOX, to extend efﬁcacy against
ﬂeas and lice. SLM also has activity against ﬂeas, as well as lice and
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are administered every 30 days during the heartworm transmis-
sion season. However, the long-acting MOX injectable preparations
ProHeart6 (and ProHeart12) provide 6 months (and 12 months)
of protection against heartworm disease by Diroﬁlaria immitis. IVM
(at 50 lg/kg) and MO are also known to kill microﬁlariae of D.
immitis and IVM has been used in a ‘‘slow kill’’ regime over 18 to
36 months to remove all stages of D. immitis, including the adult
worms (McCall, 2005). However, the recent reports of apparent
resistance to some of the ML heartworm preventatives (see below)
has led to the suggestion that the use of ML heartworm preventa-
tives in ‘‘slow kill’’ regimes should be discouraged.
4.5. Humans
IVM, as an oral tablet (Mectizan), is the only ML currently reg-
istered for use in humans. It was developed for use, at 150 lg/kg, as
a microﬁlaricide against Onchocerca volvulus, which causes river
blindness in Africa, the Arabian Peninsula and Central and South
America. In addition to its high efﬁcacy against O. volvulusmicroﬁ-
lariae, IVM also inhibits reproduction by adult O. volvulus for
6 months or more (WHO, 1995) and the combination of the anti-
fecundity and microﬁlaricidal effects reduce morbidity and para-
site transmission so that control and elimination has been
achieved in some locations with repeated annual or 6-monthly
treatments. Recently, MOX has been under evaluation for used
against human onchocerciasis (http://www.apps.who.int/tdr/svc/
news-events/news/phase3-trial-moxidectin). Based on animal
studies, the possibility that MOXmay provide greater effectiveness
than IVM against onchocerciasis is being evaluated (Etya’ale,
2001). IVM is also used in Sub-Saharan Africa for the control of
lymphatic ﬁlariasis. For this indication it is usually administered,
at 200 lg/kg, in combination with albendazole. IVM exerts similar
effects on Wuchereria bancrofti, the causative agent of lymphatic
ﬁlariasis in Africa, as it does on O. volvulus, killing microﬁlariaeFig. 2. Interaction of ivermectin (IVM) with a glutamate-gated chloride channel (GluC
superimposed over IVM (black). Note that while some of the interaction sites are shared
sites of IVM with the GluCl are either absent (C32, C33; both forming van der Waal (VDW
group in MOX, or are blocked/altered (O14; H-bond in the case of IVM) by the C23 methox
with IVM are highlighted by a solid red circle. The 25-dimethly-butyl of MOXmay also aff
10%) and C25 methyl (B1b; 90%). Against nematodes the B1b component is usually mo
this position affects potency. Thus it is likely that the 25-dimethyl-butyl group of MOX
colour in this ﬁgure legend, the reader is referred to the web version of this article.)and inhibiting reproduction of adult ﬁlarial worms for several
months. Although IVM is not registered for the treatment of soil
transmitted helminths (STH) in humans, it is known that the com-
bination of IVM with albendazole is more efﬁcacious against
Trichuris trichiura than albendazole alone (Belizario et al., 2003)
and that IVM also has activity against Ascaris lumbricoides (Stepek
et al., 2006). IVM has also proved efﬁcacious for the treatment of
strongyloidiasis and scabies in humans (Stepek et al., 2006; Shar-
ma and Singal, 2011).
4.6. Other target species
IVM, DRM and MOX are formulated for use in pigs, as oral feed
pre-mix or as injectable preparations, while IVM, EPM and MOX
are formulated as pour-ons for deer (http://www.omafra.gov.
on.ca/english/livestock/alternat/facts/info_paras.htm#anthel).
5. Pharmacodynamics
5.1. Glutamate-gated chloride channels
Ivermectin was shown to bind irreversibly to a Caenorhabditis
elegans glutamate-gated chloride channel (GluCl) subunit, ex-
pressed in Xenopus oocytes, and to open the channel with much
higher afﬁnity (EC50 of 140 nM) than the physiological ligand glu-
tamate (EC50 of 380 lM) and it has been shown that the two li-
gands share an allosteric interaction (Cully et al., 1994). The
binding characteristics of IVM and MOX to Hco-GLC-5, a subunit
of a glutamate receptor of Haemonchus contortus not found in C.
elegans, were similar in the absence of glutamate (Forrester et al.,
2002). However, 10 lM glutamate resulted in a 7-fold increase in
IVM afﬁnity, but only a 1.5-fold increase in MOX afﬁnity, suggest-
ing that while both MOX and IVM bind the same receptor site, the
interaction with the receptor is different between MOX and IVM in
the presence of the natural ligand. In another study, the effects ofl) as proposed by Hibbs and Gouaux (2011), showing moxidectin (MOX; maroon)
in common between MOX and IVM (O10, O13, C18, C35 and C48), other interaction
) interactions with the GluCl in the case of IVM) due to the absence of any saccharide
ime group of MOX. The sites where interactions will be different for MOX compared
ect interaction with the GluCl (dashed red circle). IVM is a mixture of C25 ethyl (B1a;
re potent than the B1a component, showing that the change frommethyl to ethyl at
will also affect the interaction with a GluCl. (For interpretation of the references to
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homologue of Cel-AVR-14) homomeric channel, expressed in Xeno-
pus oocytes, were compared, after wash out of glutamate, with IVM
having an EC50 of 0.5 lM, while MOX had an EC50 of 0.2 lM. In an
allele of this receptor isolated from IVM resistant C. oncophora, and
containing the L256F single nucleotide polymorphism (SNP), a sim-
ilar ratio, of MOX being approximately 2.5 times more sensitive on
the receptor than IVM, was observed, even though the 256F SNP
caused an approximate 2.5-fold decrease in sensitivity to both
IVM and MOX (Njue et al., 2004).
Recently, Hibbs and Gouaux (2011), based on the crystal struc-
ture, have proposed a model for the IVM binding site and atomic
interactions with amino acids in a homopentameric C. elegans
receptor composed of the GluCl subunit, GLC-1. Considering the
structural differences between IVM (as a representative avermec-
tin) and MOX, i.e., absence of the disaccharide moiety (or -OH)
on the C-13 of the macrocycle, a methoxime moiety at C-23 and
an oleﬁnic side chain at C-25, it can be postulated that the interac-
tion of MOX will be different from that of the avermectins. In Fig. 2,
the structure of MOX is superimposed on the proposed IVM-GluCl
interaction model (Hibbs and Gouaux, 2011). It can be seen that
some of the interaction sites (4 sites) involved with IVM binding
to the GluCl will be retained by MOX binding, but 3 of the proposed
IVM interaction sites are either not present or will be blocked
when MOX is ﬁtted to the same model. The methoxime on the spi-
roskeletal ring of MOX may prevent H-binding to a M3 loop and
may cause some molecular displacement of this loop, while the ab-
sence of the disaccharide substituent should result in MOX lacking
two van der Waal binding sites (to M2–M3 loops) to the nematode
GluCl. This suggests that MOX may interact, in some respects, dif-
ferently with GluCls. However, ﬁrm conclusions on this must await
modelling with MOX.
Nematodes have considerable diversity in GluCl subunits that
are expressed, with both C. elegans and H. contortus known to have
6 GluCl genes each and, with truncations, at least 8 different GluCl
subunit variants are expressed in each of these nematodes. How-
ever, not all of the H. contortus GluCls are homologues of those
found in C. elegans (Glendinning et al., 2011). Furthermore, in both
C. elegans and H. contortus only 4 GluCl genes, in each case, are
known to code for subunits that are sensitive to IVM. The diversity
in other parasitic nematodes is also likely to vary considerably. In
most cases, we do not yet know the speciﬁcity of different MLs for
different GluCls, or indeed for other amino-gated chloride channels
found in nematodes.
Studies have been conducted on the effects of IVM and MOX on
pharyngeal pumping and motility in adult C. elegans and on larval
development (Ardelli et al., 2009). IVM and MOX do not exert the
same effects, at similar concentrations, on this nematode. For
example, pharyngeal pumping is paralysed at approximately
5 nM by IVM, but a similar paralysis requires 80 nMMOX. In terms
of worm motility, IVM causes an initial activation of C. elegans
which is not seen after MOX exposure. Larval development is very
sensitive to IVM, being inhibited by 0.6 nM, whereas with MOX a
64-fold higher concentration is required to inhibit development.
In other experiments with adult H. contortus that were IVM-sensi-
tive, pharyngeal pumping in the presence of glutamate was also
found to be signiﬁcantly more sensitive to IVM than to MOX. In
an IVM-resistant strain of H. contortus, IVM effects on pharyngeal
pumping were signiﬁcantly decreased, while the responses to
MOX did not change in the IVM-resistant worms (Paiement et al.,
1999).
Laboratory and ﬁeld studies have shown that IVM is potently
active against Anopheles spp. mosquitoes at concentrations present
in human blood after standard drug administration. Using an
in vitro blood feeding assay, IVM and EPM were shown to be efﬁ-
cient at killing the mosquitoes at similar concentrations (LC50 of22.4 and 23.6 ng/ml, respectively), against the African malaria vec-
tor Anopheles gambiae, while MOX was 125-fold less effective (LC50
of 2789 ng/ml) (Butters et al., 2012). It is believed that the three
drugs are agonists of the insect glutamate-gated chloride ion chan-
nels. Nevertheless, it can be speculated that the differential activity
between the avermectins and MOX may originate from a lower
afﬁnity of MOX for the receptor or lower drug concentration arriv-
ing at the target.
These marked differences between responses to IVM and MOX
suggest differences at the level of GluCl interaction with avermec-
tins and MOX, or the differential involvement of other amino-gated
chloride channels with the actions of avermectins and MOX.5.2. Other amino-gated chloride channels in nematodes
Ivermectin is known to open other ligand-gated chloride chan-
nels, in addition to glutamate-gated chloride channels and GABA-
gated chloride channels (Ludmerer et al., 2002). For example, it
activates histamine-gated chloride channels in Drosophila melano-
gaster (Zheng et al., 2002) and IVM and MOX select on a dopamine-
gated chloride channel in H. contortus (Rao et al., 2009). Further-
more, there are tyrosine-gated chloride channels (Rao et al.,
2010) and serotonin-gated chloride channels (Ringstad et al.,
2009), which could be sensitive to some MLs.
GABA receptors from nematodes appear as a secondary target of
MLs (Feng et al., 2002; Beech et al., 2010) but at higher concentra-
tions than are required to open GluCl channels. According to recent
studies performed on 2 subunits of a GABA-gated chloride channel,
Hco-UNC-49B and C, both IVM and MOX were able to enhance the
response to GABA of the homomeric and dimeric channels, but by
different amounts (Brown et al., 2012). There has been a perception
that MOX and IVM act on the same receptors, but that MOX is a
more potent ligand. However, this is clearly too simplistic because
of observed differences between MOX and IVM in different ligand-
gated ion channels so far investigated. In some receptors IVM was
more potent than MOX, while in other receptors, MOX was more
potent than IVM. Thus, more investigations are needed to elucidate
the different interaction of avermectins and MOX with the large
number of ligand-gated chloride channels present in nematodes
and arthropods and to establish the full range of similarities and
differences between MOX and the avermectins on these receptors.6. Pharmacokinetics
6.1. Plasma and tissue distribution
As with any other drug with systemic action, the concentrations
and the length of residence time of the MLs in the host tissues con-
tribute to the efﬁcacy of the drug against the target parasites. Com-
pared with IVM, MOX is characterised by a larger volume of
distribution, a remarkably long mean residence time in the host
organism and both drugs have an extensive elimination in milk
during lactation (Hennessy and Alvinerie, 2002). This has been evi-
dent in several species including humans where two independent
clinical trials have been performed in healthy volunteers to evalu-
ate the safety, tolerability and pharmacokinetics of single doses of
IVM (Guzzo et al., 2002) and of MOX (Cotreau et al., 2003). Besides
a higher concentration and area under the plasma concentration
versus time curve (AUC), MOX when given orally to humans at a
dose rate averaging 0.5 mg/kg had a longer half-life and larger vol-
ume of distribution, when compared with IVM at a similar dose
rate (Table 1). Similarly in pigs, MOX kinetics were very different
from those of IVM and showed a greater apparent volume of distri-
bution, larger distribution, longer elimination half-lives and slower
clearance rate than IVM. Subsequently, MOX was detectable in
Table 1
Comparative pharmacokinetic parameters of MLs in different species. This table show example of MLs with different kinetic parameters when administered to the same species,
with same dose rate and route of administration.
Administration route (dose) AUC (ng day/ml) T1/2 (or MRT) (days) Vd(/F) (l/kg) Reference
Humans Oral (0.5 mg/kg)
Ivermectin 190 ± 79 0.8 – Cottreau et al. (2003)
Moxidectin 451 ± 48 20.2 1.2 Guzzo et al. (2002)
Pig i.v. (0.2 mg/kg)
Ivermectin 75 1.16 5.3 Craven et al. (2002)
Moxidectin 271 14 17.9
Cattle Sc (0.2 mg/kg)
Ivermectin 459 ± 47 5.5 0.45 Lanusse et al. (1997)
Moxidectin 217 ± 15 8.9 0.94
Eprinomectin 306 ± 77 6.8 Baoliang et al. (2006)
i.v. (0.07 mg/kg)
Ivermectin 211 ± 48 7.8 ± 1.6 2.72 Bousquet-Melou et al. (2004)
Moxidectin 115 ± 26 21.5 ± 1.5 14.9
Sheep Sc (0.2 mg/kg)
Ivermectin 230 3.7 – Marriner et al. (1987)
Moxidectin 161 16 – Hennessy et al. (2000)
Goat Sc (0.2 mg/kg)
Ivermectin 56 – Alvinerie et al. (1993)
Moxidectin 137 (12.4) – Escudero et al. (1999)
Eprinomectin 63 ± 23 (6.6 ± 1.3) – Lespine et al. (2003)
Rabbit Sc (0.3 mg/kg)
Ivermectin 191 2.7 Gokbulut et al. (2010)
Moxidectin 83 8.2
Dog Oral (0.25 mg/kg)
Ivermectin 233 ± 75 3.3 1.20 Al-Azzam et al. (2007)
Moxidectin 491 ± 96 25.9 0.53
AUC, area under the concentration time curve; MRT, mean resistance time; T1/2, elimination half-life; Vd(/F), apparent volume of distribution; Sc, subcutaneous.
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Altering body composition in these animals had no detectable
inﬂuence on the kinetic disposition of IVM, but MOX was distrib-
uted within and eliminated from the lean animals more rapidly
than from the fat animals (Craven et al., 2001, 2002). In horses,
MOX has a pharmacokinetic proﬁle which profoundly differs from
that of IVM and the mean residence time is fourfold higher for
MOX (18.4 days) than for IVM (4.8 days) following oral administra-
tion (Perez et al., 1999). In dogs, after oral administration, MOX has
a longer elimination half-life and larger volume of distribution
than IVM (Al-Azzam et al., 2007).
In cattle, major differences exist between IVM and MOX with a
larger volume of distribution and a faster (plasma) clearance for
MOX (Lanusse et al., 1997; Bousquet-Melou et al., 2004), presum-
ably due to a more rapid partition into adipose tissue. The mean
residence time of MOX was much longer than for IVM (24 versus
7 days, respectively) after IV injection (Bousquet-Melou et al.,
2004). In these species, the concentration of MOX in fat, 28 days
after treatment, was ninety-fold higher than in plasma and the
half-life of MOX in adipose tissue was 14 days versus 7 days for
IVM (Chiu et al., 1990).
Such differences between IVM and MOX have also been re-
ported in goats, sheep and rabbits (Marriner et al., 1987; Alvinerie
et al., 1993; Escudero et al., 1999; Hennessy and Alvinerie, 2002;
Gokbulut et al., 2010) (Table 1). It is noteworthy that EPM presents
pharmacokinetics close to IVM in cattle and in goats (Lespine et al.,
2003; Baoliang et al., 2006) (Table 1), in agreement with the struc-
tural similarities of the two drugs.
A close correlation between the drug disposition in the plasma
and in tissues where parasites live, such as the gastrointestinal
tract, skin or lung has been established for MOX in cattle (Zulalian
et al., 1994; Lifschitz et al., 1999; Sallovitz et al., 2003) and for IVM
in other species (Chiu et al., 1990; Lespine et al., 2003) and there-
fore plasma drug concentration is considered as a good predictor ofanthelmintic efﬁcacy for MLs. The longer persistence of MOX con-
centration in these tissues when compared with IVM is in accor-
dance with the longer persistence of MOX activity.
MLs can be formulated differently and the formulation can af-
fect the initial absorption process. But when focusing on the late
elimination phase, reﬂected in the half-life of elimination, these
differences are likely to be related to the lipophilicity and efﬂux
potential, via ABC transporters. Indeed, fat is known to act as a res-
ervoir for lipophilic compounds and the higher lipophilicity of
MOX compared with IVM or EPM (logPMOX = 6; logPIVM = 4.8; log-
PEPM = 4.0) favours MOX retention in fatty tissue and longer elimi-
nation half-life. In addition, given the higher capacity of IVM to be
actively efﬂux out of the organisms compared with MOX (see par-
agraph 6), ABC transporters also contribute to the different kinetics
in the host observed between the two MLs.
6.2. Elimination in milk
The mammary gland epithelium, like other biologic mem-
branes, acts as a lipid barrier, and the high lipophilicity of the
MLs is in favour of partitioning into milk. Milk/plasma concentra-
tion ratios close to unity have been reported for IVM in many spe-
cies (Table 2). However, one of the studies reported a higher milk/
plasma ratio of 2.5 ± 0.4 in sheep (Imperiale et al., 2004). The
amount of lipid in sheep milk is twice the amount found in other
species which may explain the higher rate of IVM transfer into milk
in this species. The partitioning of MOX into milk is higher than
that of IVM with milk/plasma concentration ratios ranging from
4.2 to 18.5 in different animals, and with a huge MOX elimination
occurring in sheep milk (Imperiale et al., 2004). This is consistent
with the higher lipophilicity of MOX compared with IVM, and with
the high fat content of sheep milk. As expected, EPM has a lower
rate of milk partitioning in the cow (Alvinerie et al., 1999c) and
in the goat (Alvinerie et al., 1999a), allowing for its use in lactating
Table 2
Comparative ratio of area under the concentration time curves AUC milk/AUC plasma of MLs in different species.
Humans Cattle Buffaloes Sheep Goat Camel
Ivermectin 0.6a 0.8 (Toutain et al.,
1988)
– 1.0 (Bogan and
McKellar, 1988)
2.5 ± 0.4 (Imperiale
et al., 2004)
1.1 ± 0.2 (Alvinerie
et al., 1993)
1.2 ± 0.4 (Oukessou
et al., 1999)
Eprinomectin – 0.1b (Alvinerie et al.,
1999a,b,c)
0.8 ± 0.2 (Dupuy
et al., 2008)
0.8 (Hodoscek et al.,
2008)
0.1–0.2 (Dupuy et al.,
2001)




– 5.0 ± 2.1 (Dupuy
et al., 2008)
18.5 ± 1.2 (Imperiale
et al., 2004)
7.5 (Carceles et al.,
2001)c
4.2 ± 0.7 (Oukessou
et al., 1999)
–: Not determined.
a Extrapolation from data of Guzzo et al. (2002) and Ogbuokiri et al. (1993).
b 0.094 in zebu gobra (Bengone-Ndong et al., 2006).
c Estimation.
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ing of EPM is close to that of IVM (Bengoumi et al., 2007; Dupuy
et al., 2008; Hodoscek et al., 2008), suggesting that factors other
than drug lipophilicity and milk fat composition are involved in
the partitioning of this anthelmintic. In humans, IVM (Ogbuokiri
et al., 1993) and MOX (Korth-Bradley et al., 2011) have been eval-
uated in breast milk and although the partitioning of MOX remains
higher than that of IVM, it is lower than in other species.6.3. Biotransformation
Enzymes can metabolise MLs in mammals (Chiu et al., 1987)
and in nematodes (Alvinerie et al., 2001), contributing to drug
elimination and modifying drug disposition. On the basis of radio-
activity recovered in faeces after 3H-IVM administration, it was
shown that the major component excreted was the parental com-
pound. Nevertheless, a substantial amount of radioactivity was ac-
counted for in the metabolites (Hennessy and Alvinerie, 2002). IVM
was metabolized in rat microsomes and the main metabolite de-
tected was 24-hydroxy-IVM. In pigs and goats, the main metabolite
detected was O-desmethyl-IVM. In humans, the major metabolites
formed by liver microsomes were the 24-monohydroxylated and
3-O-demethyl metabolites. Cytochrome P450 3A4 was identiﬁed
as the predominant enzyme involved in IVM metabolism (Zeng
et al., 1998).
MOX produces essentially C29-30- and C14-mono-hydroxy-
methyl derivatives as metabolic products (Zulalian et al., 1994),
which are formed by the cytochrome P450 3A (Dupuy et al.,
2001) and cytochrome P450 2B (Dupuy et al., 2001). In cattle, the
fractions metabolized were found to be around 8% for IVM and
13% for MOX. The higher clearance of MOX in cattle after IV admin-
istration (Lanusse et al., 1997; Bousquet-Melou et al., 2004) could
be due to higher metabolism or larger distribution compared with
IVM. However, metabolism is considered to contribute only to a
small extent to ML elimination compared with elimination of
parental compound via efﬂux transporters.7. Interaction of avermectins and moxidectin with mammalian
multidrug ABC transporters
Efﬂux of MLs via active transport from mammalian and parasite
cells are especially important. The transporters involved strongly
inﬂuence the pharmaco- and toxicokinetics of these drugs. Their
presence at the intestinal level contributes extensively to the elim-
ination of these drugs in the faeces. In addition, being located in
the blood–brain barrier, they limit the net entrance of the drug into
the brain which explains the low toxicity of the MLs in most mam-
mals (Lespine et al., 2009; Kiki-Mvouaka et al., 2010).ATP-binding cassette (ABC) transporters include P-glycoprotein
(P-gp or MDR1 of the ABCB family), the Multidrug Resistance asso-
ciated Proteins (MRPs of the ABCC family) and the ‘half-trans-
porter’ subfamily, Breast Cancer Resistance Protein (BCRP or
ABCG2) (Doyle and Ross, 2003). These transporters are found on
barrier epithelia such as intestine, plancenta, mammary gland
and the blood–brain barrier. The complexity and also the perfor-
mance of the system lies in the ubiquitous presence of different
transporters expressed at various levels and presenting consider-
able overlap in their substrate speciﬁcities. By their action, these
transporters provide an efﬁcient barrier of protection for the
organism from the toxicity of most contaminants and they limit
the entrance of many drugs, restricting their efﬁcacy. They also
play a clinically relevant role in drug interactions when drugs are
combined (Sarkadi et al., 2006). Many ABC transporters are also
found in nematodes, protozoa, fungi and bacteria and some of
them are involved in drug resistance in these organisms. Indeed,
drug resistance in pathogens is very commonly associated with
alterations in drug transport, resulting in lower drug concentra-
tions at the site of the relevant drug receptor(s) than in susceptible
strains.7.1. Molecular interaction of avermectins and moxidectin with P-
glycoprotein
Among the MLs only IVM has, so far, been reported to be a sub-
strate of P-gp and is also known to be an inhibitor of P-gp-medi-
ated transport (Didier and Loor, 1996). This has been shown by
different approaches. Firstly, by measuring the capacity of IVM to
inhibit the efﬂux of rhodamine 123, a ﬂuorescent substrate of P-
gp, it has been shown that IVM is one of the most potent known
inhibitors of P-gp (Eneroth et al., 2001). Secondly, the ATPase activ-
ity of the transporter is inhibited by IVM (Lespine et al., 2007). This
suggests that the molecular basis for inhibition of P-gp by IVM lies
in the fact that this drug and certainly other avermectins are slowly
transported by P-gp blocking the binding site for other compounds.
Later, by studying the molecular interactions of several MLs
with P-gp, it became evident that there are major differences be-
tween MOX and avermectins which can account for the differences
in their kinetics. All avermectins interfered with P-gp transport
activity with a similar potency as IVM. By contrast, MOX was found
to be a poor inhibitor of the P-gp-mediated rhodamine123 trans-
port compared with IVM, SLM, EPM, ABM or DRM. Another ap-
proach showed a differential effect of the avermectins and MOX
with P-gp ATPase activity (Lespine et al., 2007). Based on the
capacity of different MLs to inhibit verapamil ATPase activation,
it is possible to localise their association on the drug binding site
of the P-gp and to determine their inhibitory constant (Ki). This
conﬁrmed that MOX has a weaker afﬁnity than the avermectins
Table 3
Relation between the ability of MLs to inhibit the P-gp transport activity, to modulate ATPase activity and their lipophilicity.
In LLCPK1-mdr1a cells ATPase activity in P-gp overexpressing vesicles ML lipophilicity






Ivermectin 0.44 0.05 4.8
Eprinomectin 0.50 0.02 4.4
Abamectin 0.11 0.02 5.3
Doramectin 0.31 0.03 5.6
Selamectin 0.60 1.0 6.3
Moxidectin 4.4 0.5 6
ATPase activity of P-gp was measured on membrane vesicles prepared from Chinese hampster cells overexpressing P-gp, in the presence of 5 mM ATP and ivermectin (0.05–
100 lM). ATPase activity was ﬁrst activated by verapamil (40 lM). IC50 is deﬁned as the ivermectin concentration that inhibits by 50% the activated ATPase activity. The Ki of
ivermectin was calculated as follows:
K i ¼ IC50  KactKact þ ðSÞ
where IC50 was determined for ivermectin for each transporter inhibition assay; (Ss) was the concentration of the reference activator used in
the inhibition assay; Kact was the concentration of the reference activator that allowed half maximum ATPase activation of the corresponding
transporter.
a HyperChem 7.0, HyperCube Inc.
b Garrigues et al. (2002).
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charide moiety present on avermectins (excluding selamectin
which has only one sugar) plays a determining role in the afﬁnity
for P-gp (Lespine et al., 2007). The presence or absence of the
somewhat lipophilic sugar groups changes the physico-chemical
properties of the drug. Indeed, the hydrophobicity of the molecule
dictates its partitioning within the lipid membrane, which is an
obligatory ﬁrst step for the interaction of a substrate with P-gp.
The presence of the sugar moieties inﬂuences the degree of hydro-
phobicity of the molecule, and a relationship has been proposed
between the octanol/water partition coefﬁcient (logP) of the MLs
and the afﬁnity for P-gp. The logP, calculated by using atomic
parameters (HyperChem 7.0, HyperCube Inc. (Vellarkad et al.,
1989)) are 6 and 6.3 respectively for MOX and SEL, while the other
MLs have lower partition coefﬁcients (4.8, 4.4, 5.3 and 5.6 for IVM,
EPM, ABM and DRM, respectively).
The presence or absence of the sugar part of the drug also
changes the steric hindrance of the drug which can impact on the
binding of the drug to the transporter. Data on the interaction with
P-gp, obtained with DRM and SLM are very informative because the
core of the chemical structure of these two avermectins is similar
and they mainly differ by the presence of one sugar for SLM and 2
sugars for DRM. On the basis of the different ability of DRM and
SLM to compete with verapamil on P-gp, it can be suggested that
the second sugar unit plays an important role in the interaction
with P-gp. These observations are consistent with the role of the su-
gar groups in governing the ability of MLs to interact with the P-gp
drug binding sites (Lespine et al., 2007) but it cannot be excluded
that other functions that characterise MOX are also important such
as the oleﬁnic side chain at the 25-position and the methoxime
moiety at the 23-position. The P-gp substrate drug cyclosporin A
has been extensively studied as a strong P-gp inhibitor. Comparison
between cyclosporin and IVM shows both compounds are strong P-
gp inhibitors that are rich in hydrogen bonds inducing a slow trans-
port (Saeki et al., 1993; Pouliot et al., 1997), possibly as a result of
lower dissociation rates from the protein (Seelig and Gerebtzoff,
2006). Both interfere with calcein-acetoxymethyl ester transport
in CaCo-2 cells with similar efﬁcacy (Eneroth et al., 2001) and show
similar competition with P-gp speciﬁc antibodies (Nagy et al.,
2004). Cyclosporin A also competes with IVM on membranes fromdrug-resistant cells overexpressing P-gp (Pouliot et al., 1997). In
membrane vesicles overexpressing P-gp, cyclosporin A competed
with verapamil displaying a Ki for P-gp of 0.015 lM (Garrigues
et al., 2002), which is comparable to the one calculated for the aver-
mectins (0.02–0.05 lM) (Lespine et al., 2006). Altogether, these re-
sults support the view that cyclosporin and avermectins share a P-
gp binding site also common to verapamil. Based on an integrated
approach using enzymatic assays and in silico molecular modelling
of some P-gp substrates, a two pharmacophoremodel has been pro-
posed (Garrigues et al., 2002), with at least two close hydrophobic
pockets within P-gp able to bind speciﬁc compounds. One has been
shown to bind verapamil and the other tentoxine. The similar com-
petitive effect of cyclosporin A and IVM on verapamil and on vari-
ous other P-gp substrates, such as calcein or tentoxine, is the
consequence of the large molecular size of the drugs leading to
overlapping binding on the two P-gp recognition sites. With regard
to the interactive function, it is likely that for IVM, themacrolactone
and the hexahydrobenzofuran unit, which constitute the core of the
ML, participate in its binding to P-gp while the disaccharide moiety
is probably involved at an additional binding site, further increasing
afﬁnity. On the basis of structural analogy and on biochemical stud-
ies showing competition with verapamil (Lespine et al., 2006) and
tentoxine (Lespine, unpublished data), MOX may bind similarly to
the two binding sites of verapamil and tentoxine on P-gp. However,
with MOX, the absence of the disaccharide prevents the binding to
the third putative IVM binding site and leads to weaker binding.
Such an approach to study and compare the interactions of drugs
with the binding sites of the transporter is of interest in order to
predict drug-drug interactions or to design effective inhibitors of
the transporter.
7.2. P-gp contributes to the pharmacokinetics of avermectins and
moxidectin
P-gp is also located on the apical surface of the enterocytes and
hepatocytes, and thus expels drugs into the intestinal lumen and
the bile. A strong accumulation of IVM (10-fold) occurred in gall
bladder cells of P-gp deﬁcient mice (Schinkel et al., 1994) and bil-
iary secretion was originally thought to be the major route of ML
excretion (Hennessy and Alvinerie, 2002). Nevertheless, P-gp-med-
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in the overall elimination of IVM in rodents (Laffont et al., 2002;
Ballent et al., 2006; Kiki-Mvouaka et al., 2010). These results sup-
port the extensive elimination of avermectins by the faecal route
and the main consequence of P-gp action is to limit the systemic
level of IVM and the duration of animal drug exposure and subse-
quently the drug efﬁcacy.
A recent study comparing the kinetics of MLs in P-gp deﬁcient
mice revealed major differences in the contribution of P-gp to
the disposition of MOX compared with avermectins. EPM is efﬁ-
ciently efﬂuxed by P-gp which is consistent with its higher afﬁnity
for the transporter when compared with IVM and MOX. The plas-
ma kinetics of MOX are not inﬂuenced by the lack of P-gp in mice,
while pharmacokinetic parameters for IVM are strongly affected by
the presence or absence of P-gp, and even more so for EPM. The
AUC was more than doubled for IVM and EPM and was unchanged
for MOX, in P-gp deﬁcient mice compared with wild-type. There-
fore it can be concluded that IVM and EPM are actively excreted
from the intestine via an active P-gp-dependent pathway, while
MOX is mostly excreted via a P-gp-independent pathway at the
intestinal barrier (Kiki-Mvouaka et al., 2010). Similarly, IVM is ac-
tively transported via P-gp into the apical compartment in polar-
ised CaCo-2 cells and MOX is not (Grifﬁn et al., 2005).
Surprisingly, there are several other data showing that the behav-
iour of MOX in the host organism is controlled by P-gp or related
transporters. In vivo, MOX is efﬂuxed out of the brain at the
blood–brain barrier level as testiﬁed by the low concentration of
the drug in the brain of control mice versus the higher concentra-
tion of MOX in the brain of P-gp deﬁcient mice. Because in the
same study, P-gp did not appear to contribute to MOX efﬂux at
the intestinal level (Kiki-Mvouaka et al., 2010), these results sug-
gest tissue speciﬁcity in the P-gp efﬂux capacity of MOX. Also,
the accumulation of MOX into rat hepatocytes was increased by
inhibitors of P-gp or of other ABC transporters showing their pos-
sible involvement in MOX efﬂux out of these cells (Dupuy et al.,
2006). In addition, in vivo studies based on co-administration of
P-gp inhibitors with MLs suggested that MOX kinetics was some-
what dependent on P-gp or another ABC transporter. Loperamide,
known to be a potent P-gp inhibitor, induced changes in the phar-
macokinetic behaviour of both IVM and MOX in cattle. When asso-
ciated with loperamide, both drugs showed increased AUC, but for
IVM the absorption was increased while for MOX the elimination
rate was decreased. This may reﬂect differences in the process of
P-gp-mediated transport for the two drugs (Lifschitz et al., 2010).
Similarly, the co-administration of ketoconazole was able to in-
crease IVM AUC in sheep (Alvinerie et al., 2008) and also that of
MOX (Dupuy et al., 2003). However, in another study where verap-
amil was co-administered with MOX or with IVM, only the IVM
kinetics were impacted whereas the MOX kinetics were unchanged
(Molento et al., 2004).
Because MLs are P-gp substrates and also lipophilic drugs, their
behaviour inside the body is expected to be the resultant of two
main driving forces: the P-gp efﬂux and their afﬁnity for adipose
tissue. The balanced of the two actions is related to the logP of each
ML, and inversely related to the drug afﬁnity for P-gp. The higher
the afﬁnity of the ML for P-gp, the more efﬁciently the drug is eff-
luxed via the transporter out of the tissue or the organism. Given
that IVM and EPM display higher afﬁnity for P-gp than MOX does
(Lespine et al., 2007), it is reasonable to assume that the elimina-
tion of EPM is mainly due to its high afﬁnity for P-gp and its lower
hydrophobicity (Table 3, logP = 4; Ki = 0.02 lM) which results in a
lower attraction to the adipose tissue, in accordance with its lower
persistence in the plasma (MRT) and the lower entrance into the
brain. In contrast, the higher lipophilicity and lower afﬁnity for
P-gp of MOX (logP = 6; Ki = 0.5 lM), is consistent with fat accumu-
lation, to the detriment of P-gp efﬂux. Therefore, MOX behaviour inthe host appears to be governed mainly by lipophilicity resulting in
a relative delay in drug elimination and to a prolonged MRT. Final-
ly, IVM having intermediate lipophilicity and afﬁnity for P-gp
(logP = 4.8, Ki = 0.05 lM), displays an intermediate behaviour be-
tween EPM and MOX and is equally governed by both factors.
7.3. Interaction of avermectins and moxidectin with other efﬂux
transporters
Since BCRP (ABCG2) is co-localised with P-gp on the major epi-
thelial barriers such as the intestine and the blood–brain barrier, it
may contribute signiﬁcantly to the transport of a number of sub-
strates. This has therapeutic and physiological implications in hu-
mans and in animals (Mealey, 2011). Both IVM and MOX interact
with BCRP (ABCG2), and thus we cannot exclude the possibility
that this transporter also plays a role in the pharmacokinetics of
both avermectins and MOX. IVM efﬁciently inhibits human (Muen-
ster et al., 2008; Jani et al., 2010) and sheep BCRP (Real et al., 2011).
No data are available on the direct transport of IVM by BCRP. Nev-
ertheless, MOX was identiﬁed as a BCRP substrate because of its
Bcrp1-mediated secretion into breast milk and the involvement
of Bcrp1 in intestinal and bile secretion of MOX (Perez et al.,
2009). However, the interactions of MOX and avermectins with
BCRP have not yet been parameterized. Given the role of BCRP in
the efﬂux of substrates into the milk (Jonker et al., 2005), these
interactions of avermectins and MOX with BCRP will have pharma-
cokinetic, toxicological and milk residue consequences. Indeed, the
low elimination of EPM in milk compared with other MLs could be
due to a lower transport of this drug by BCRP.
IVM also interacts with MRPs (ABCCs). Data showing the lower
accumulation of IVM in cells overexpressing MRP1 together with
the polycyclic structure and lipophilic nature of IVM strongly sug-
gest that IVM could also be a MRP transport substrate, even though
no transport was shown in polarised cells overexpressing MRP1
(Brayden and Grifﬁn, 2008). IVM inhibits the calcein transport
mediated by MRP1 and to a lesser extent that by MRP2 and
MRP3 (Lespine et al., 2006). However, the inhibitory potency of
IVM with MRPs is weak compared with its interaction with P-gp,
and data on interaction of MOX with MRPs is lacking.
7.4. Avermectins and moxidectin modulate the expression of
mammalian efﬂux transporters
Another possible interaction between MLs and MDR efﬂux
transporters concerns the ability of the drug to modulate the
expression of transporter genes. Considerable evidence has accu-
mulated to indicate that the expression of drug transporter genes
can be rapidly and transiently induced following treatment by che-
motherapeutic agents (Chin et al., 1990). The subsequent change in
the activity of the transporter can have a major impact on metab-
olism, toxicity, drug-drug interactions and the efﬁcacy of drugs. In-
deed, even a moderate increase of P-gp expression was shown to
be associated with resistance to the anticancer drug doxorubicin
(Pajic et al., 2009).
IVM was shown to induce the expression of the mdr1 gene
encoding for P-gp in mouse hepatocyte cell lines, which was asso-
ciated with increased efﬂux activity of P-gp (Menez et al., 2012). In
another study using adriamycin-resistant cancer cells overexpress-
ing P-gp, a 24 h exposure to DRM or nemadectin led to a decrease
in the expression of the P-gp gene (Gao et al., 2010). The different
responses may be due to the differences in cell models; the second
study being performed in cells considerably overexpressing P-gp,
while the ﬁrst one used hepatocytes with relatively low constitu-
tive expression of the P-gp gene. We can expect that the regulatory
mechanism in the two models is different. The IVM P-gp induction
occurred through increasing the mRNA half-life (Menez et al.,
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creased the P-gp gene expression, have not been investigated. Nev-
ertheless, in the study using drug resistant cancer cells, the P-gp
gene down-regulation was more pronounced in the presence of
DRM than with nemadectin suggesting differences in the potency
of DRM and the milbemycin in regulating P-gp gene expression.
Deciphering the respective contribution of avermectins and
MOX to the regulation of the detoxiﬁcation network controlling
gene expression of transporters will help in the understanding of
the differences in the occurrence of resistance under avermectin
or MOX pressure.7.5. Avermectins and moxidectin as multidrug resistance reversing
agents in cancer cells
A common mechanism that confers simultaneous resistance to
different drugs, based on drug efﬂux from cells or organisms med-
iated by multidrug ABC transporters, represents a critical phenom-
enon hampering anticancer, antibacterial, antifungal and
antiparasitic chemotherapy. Because the afﬁnity of avermectins
for P-gp is among the highest described to date, they compete with
a large number of P-gp substrates (Lespine et al., 2008). In addition,
they also inhibit MRP1 and BCRP which makes their action not re-
stricted to P-gp and, at least theoretically, makes it possible to de-
sign an efﬁcient broad-spectrum MDR reversal agent, active
whatever the relevant MDR transporter involved.
The high efﬁciency of MDR reversal by avermectins was demon-
strated in cultured tumour cells overexpressing P-gp. IVM was able
to increase vinblastine efﬁcacy in vinblastine-resistant human lym-
phoma cells (Pouliot et al., 1997). In vincristine-resistant human
lympholeukemic cells P388 and in taxol-resistant larynx tumour
Hep-2 cells, IVMwasmore effective than the traditionalMDR trans-
port inhibitor cyclosporin A (Korystov et al., 2004). Some avermec-
tin aglycone compounds were recently shown to be also potent
MDR reversing agents in adriamycin-resistant cancer cells over-
expressing P-gp (Gao et al., 2011). However, DRM was more potent
in reversing MDR than the milbemycin, nemadectin (Gao et al.,
2011). Because nemadectin, the parent compound used for MOX
production, is structurally closely related to MOX and also lacks a
disaccharide moiety, its lower capacity to reverse MDR is probably
linked to its lower ability to interact with P-gp (Gao et al., 2010).
This is in agreement with the weaker interaction of MOX with
P-gp and the relationship between structure and function in terms
of the interaction of MLs with P-gp (Lespine et al., 2007).
Owing to the strong interaction of avermectins with the MDR
transporters, they have been proposed as possible reversal agents
to potentiate chemotherapy based on MDR transporter substrates.
However, such a possibility was rejected because of the potential
neurotoxicity of avermectins which dictates caution for their use
in humans, in particular when co-administered with another
MDR substrate and potential MDR inhibitor in clinical situations.
In this respect, it would also be of major interest to know the abil-
ity of different MLs to bind to mammalian GABA receptors impli-
cated in their mammalian neurotoxicity.8. Toxicology
8.1. Receptor selectivity and the toxicology of the avermectins and
moxidectin
As discussed in the section on pharmacodynamics, the primary
receptors for ML anthelmintics appear to be glutamate-gated
chloride channels which occur in nematodes and some arthropods,
but do not occur in mammals. Thus the lack of these receptors in
mammalian hosts provides some measure of safety from ML toxic-ity in mammals. Nevertheless, MLs also act on GABA-gated chlo-
ride channels, although in nematodes these GABA channels
appear to be less sensitive than some GluCl receptors. GABA recep-
tors are expressed in the central nervous system (CNS) of mam-
mals. Thus, there is the potential for mammalian toxicity if
moderately high levels of some MLs reach the brain. Fortunately
in mammals, the ABC transporters located at the blood–brain bar-
rier normally exclude most MLs, such as IVM, from reaching GABA
receptors in the CNS at concentrations that would induce toxicity.
Thus the interplay between receptor sensitivity and integrity of the
exclusion function of the blood–brain barrier are vitally important
in safety and toxicity of MLs and the interaction of different MLs
with the blood–brain barrier ABC transporters and the brain’s
GABA receptors will inﬂuence their relative toxicity.8.2. Contribution of P-glycoprotein to toxicity of avermectins and
moxidectin in dogs
Since the link between IVM and P-gp was found, a considerable
body of research has been carried out in order to throw light on the
role of P-gp in IVM toxicology and pharmacology. Indeed, IVM was
the ﬁrst ML designated as a P-gp substrate when genetically engi-
neered mice lacking the gene coding for P-gp (mdr1a/) were
treated with a standard antiparasitic procedure in the animal facil-
ity. The treated P-gp gene-mutated mice showed signs of toxicity,
and nearly all those homozygous for the mutation died; they were
found to have a 100-fold higher IVM concentration in their brain
than the wild type mice (Schinkel et al., 1994). This is consistent
with the property of avermectins to bind to GABA receptors in
the CNS of mammals.
P-gp is thus clearly responsible for preventing IVM from enter-
ing the brain tissue, and its role is extended to controlling the tis-
sue distribution of the drug in the whole organism (Schinkel et al.,
1994). IVM hypersensitivity with neurotoxicity is also observed in
a subpopulation of CF1 mice that are mutated and do not produce
P-gp (Kwei et al., 1999). The identiﬁcation of subpopulations of
Collie dogs and other herding breeds that display a similar sensitiv-
ity, to IVM, as P-gp knockout mice (Paul et al., 1987), has consider-
ably broadened clinical interest of P-gp in the canine veterinary
clinic. As expected, P-gp deﬁcient dogs are also sensitive to other
drugs which are substrates of P-gp and develop a neurotoxic effect
with compound such as loperamide (Hugnet et al., 1996; Sartor
et al., 2004) and vincristine (Krugman et al., 2011).
A deletion mutation of the gene encoding P-gp exists in IVM-
sensitive Collies and produces a frame shift that generates a pre-
mature stop codon in the MDR1 gene resulting in a severely trun-
cated, nonfunctional protein (Mealey et al., 2001; Roulet et al.,
2003). The P-gp gene mutation in Collies appears to be widely dis-
tributed in the population with 35% of Collie dogs homozygous for
the mutant allele and 42% heterozygous (Mealey et al., 2002;
Hugnet et al., 2004; Neff et al., 2004; Geyer et al., 2005a; Geyer
and Janko, 2011). Several other herding breeds including the
Shetland Sheepdog, Australian Shepherd, Old English Sheepdog,
Border Collie, Longhaired Whippet, Silken Windhound, McNab,
English Shepherd, and Swiss White Shepherd breeds have also
been identiﬁed to carry the mutation. Anecdotal reports of IVM
toxicity in cats after standard doses have been published, but
whether or not the underlying cause is a result of altered P-gp
expression or function is not currently known (Pritchard, 2011).
Apart from SLM, avermectins are rarely used in cats, and so less
information is available regarding the toxicity of different aver-
mectins, and the functioning of P-gp at the blood–brain barrier in
cats. However, SLM as Revolution, and MOX as Advantage Multi
topical solutions, as well as MO as Milbemax tablets, are widely
used in cats and have excellent safety.
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ence adverse neurologic effects after a single dose of IVM (120 lg/
kg) and are also sensitive to toxic effects of some other avermec-
tins. Different MLs have different toxicity, not only in their target
parasites but also in mammals, and ABM is known to be more
toxic, and MOX less toxic when compared with IVM. However,
although several studies have addressed the toxicity of the differ-
ent MLs in the host, it is sometimes difﬁcult to extract clear
information.
CF1 mice lacking P-gp are sensitive to the neurotoxicity induced
by IVM and are also sensitive to ABM and the toxic effects are vis-
ible at 0.2 mg/kg for IVM and 0.075 mg/kg for ABM, supporting the
higher toxicity of ABM compared with IVM. It has been suggested
that these differences may be due to differences in accumulation of
these compounds in the brain (Lankas et al., 1997, 1998) and may
also be caused by different interactions with brain GABA receptors.
In parallel with these studies, clinical observations have shown
that the two avermectins, IVM and DRM, at doses of 0.2 and 0.2–
1.0 mg/kg, respectively, provoke severe signs of neurotoxicosis in
P-gp deﬁcient dogs, including apparent depression, ataxia, somno-
lence, mydriasis, salivation, and tremor (Paul et al., 1987; Hopper
et al., 2002; Yas-Natan et al., 2003; Geyer et al., 2007). On the other
hand, SLM produced no severe signs of toxicosis at a topical dose
rate of 40 mg/kg, or an oral dose rate of 15 mg/kg, which are three
to seven times the recommended dose rates (Bishop et al., 2000;
Novotny et al., 2000). However, IVM sensitive Collies have been
shown to be also sensitive to the effects of MO administered at
10 mg/kg (20 times the recommended dose rate); a similar margin
of safety as IVM. Adverse reaction (neurological toxicity) was ob-
served after treatment with milbemycin 5-oxime with an oral dose
ranging from 1.0 to 2.2 mg/kg per day (Barbet et al., 2009). How-
ever, milbemycin 5-oxime at lower doses, up to 5 and 10 times
the maximum label dose rate, and combined with spinosad, ap-
pears to be safe in P-gp deﬁcient dogs and no signs of toxicosis
were observed in dogs with the P-gp gene mutation (Sherman
et al., 2010).
MOX administered to P-gp deﬁcient dogs, sensitive to a dose of
IVM of 120 lg/kg that corresponds to 20 times the recommended
dose for heartworm prevention, produced no signs of toxicosis in
any dog receiving MOX orally at 30, 60, or 90 lg/kg (up to 30-fold
the monthly heartworm prophylaxis oral dose rate), revealing that
the MOX heartworm monthly prophylaxis formulation used in the
study has a wider margin of safety than IVM in avermectin-sensi-
tive Collies (Paul et al., 2000). However, there is a report of one
Australian Shepherd dog, which was homozygous for the mdr1 de-
fect, and which received 0.4 mg/kg MOX orally, showing neurotox-
icity (Geyer et al., 2005b). Surprisingly, the same dog had been
treated daily for 7 days with 0.1 mg/kg of MOX orally without
any signs of toxicosis. After showing signs of toxicosis following
treatment at 0.4 mg/kg, the dog received diazepam (IV) and fully
recovered by 48 h after high dose MOX administration. When sim-
ilar avermectin-sensitive Collie dogs having toxicosis signs at
120 lg/kg of IVM, were subsequently exposed to up to 32.5 mg/
kg moxidectin (270 times the IVM dose rate to which they were
sensitive) they showed no signs of toxicity to MOX (Paul et al.,
2004). In this study, MOX (and imidacloprid in combination) was
applied topically which administration route is well known to be
associated with a relatively low systemic drug concentration (for
a given dose rate) compared with oral administration, and the
MOX was co-administered with 26–130 mg/kg imidacloprid.
Considered together, these studies suggest that MOX is much safer
than IVM in the P-gp deﬁcient dogs. However, in another case
report, three dogs which were not defective in the mdr1 gene
(normals), accidentally orally ingested the topical endectocide
formulation. They consumed between 1.89–2.85 mg/kg of MOX
and 7.54–11.4 mg/kg of imidacloprid and showed intoxicationwith signs of ataxia, generalised muscle tremors, paresis, hypersal-
ivation and disorientation (See et al., 2009). All three dogs, after
gastrointestinal decontamination, ﬂuid and benzodiazepine ther-
apy made complete recoveries within 48 h of ingestion. As imida-
cloprid is a nicotinic agonist and the dogs ingested a topical
formulation designed to maximise dermal absorption, it is not
clear from these cases how much of the observed toxicity was
due to MOX and/or the likely very rapid rate of absorption. In
chronic toxicity studies Beagle dogs (normal) receiving MOX orally
at between 2 and 4 mg/kg/day for 5 days (10–20 mg/kg total dose
over 5 days) showed clinical, but non-lethal signs similar to those
that were observed in the case report on the three intoxicated dogs
(WHO, 1996). The relatively similar low toxicity response to MOX
in mdr1 defective and normal dogs suggests that a fully functional
blood–brain barrier may be less important for MOX safety than is
the case with IVM and other avermectins in which a fully func-
tional blood–brain barrier is critically important to achieving
safety in mammals.
As mentioned above, differences between the toxicity of differ-
ent MLs could be related to the drug penetration into the brain in
the absence of P-gp, the dose and the interaction of different MLs
with GABA receptors in the mammalian brain. It is of special
interest in such studies to monitor the drug concentrations in
the animals together with any toxicity signs in order to under-
stand the risk of toxicity. To address this question, studies have
been performed in P-gp-deﬁcient mice by comparing MLs admin-
istered at similar dose rates and route of administration and by
measuring drug concentrations in the brain. It was shown that
IVM, EPM and MOX levels were very low in the brain of wild-type
mice while the three drugs accumulate in the brain of P-gp-
deﬁcient mice. These data reveal that P-gp at the blood–brain bar-
rier efﬂuxes out not only IVM but also EPM, and to a lesser extent
MOX. MLs appeared to have different abilities to be expelled out
of the brain via a P-gp-dependent pathway. Indeed, the data
showed that P-gp contributes considerably to preventing IVM
and EPM penetration into the brain, while this transporter has a
relatively lower contribution in controlling the entrance of MOX
(Kiki-Mvouaka et al., 2010). Other work showed that SLM is efﬁ-
ciently expelled out of the brain by P-gp but accumulates to a les-
ser degree than IVM in the brain of P-gp-deﬁcient mice (Geyer
et al., 2009). In this study, IVM was used at a standard therapeutic
dose rate of 0.2 mg/kg, and SLM was applied at the maximum
therapeutic dose rate for the body weight range of 12 mg/kg.
Based on the 60 times higher dose rate of SLM used, compared
with IVM, these data suggest that SLM has a higher safety margin
in P-gp-deﬁcient dogs than IVM, as has been described above. The
lower CNS toxicity provoked by MOX and SLM compared with
IVM, ABM, DRM and EPM suggests also that the two drugs may
interact differently with GABA receptors. Indeed, MOX and SLM
have lower afﬁnity for mammalian P-gp than do IVM, ABM,
DRM and EPM (see Table 3 for Ki values) and this difference has
been related to their structures (Lespine et al., 2007). Although
no data are available on MOX and SLM interaction with GABA
receptors, we cannot exclude that the ML structures determine
different interaction with GABA receptors.
8.3. Toxicity of ivermectin in humans: severe adverse events
It has been known for some time that severe adverse events
(SAEs) can occur, rapidly after IVM treatment, in some individual
humans carrying high burdens of the ﬁlarial nematode Loa loa
(Gardon et al., 1997; Boussinesq et al., 1998; Pion et al., 2006),
including death. Over 130 human SAEs, including mortalities due
to IVM, have been recorded. A high L. loa microﬁlaraemia (e.g.
30,000 microﬁlariae/ml blood) seems to be a pre-condition for
these SAEs. However, some individuals with high L. loa microﬁlar-
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in addition to L. loa, some other factor(s) may predispose some
individuals to IVM SAEs. Men tend to have higher burdens of L.
loa and are more predisposed to IVM SAEs than women and this
is thought to be genetic/physiological rather than environmental.
A recent study on a small number of IVM SAE patients indicated
that a genetic change in the mdr1 gene may be associated with a
predisposition to IVM SAEs (Bourguinat et al., 2010). Mdr1 poly-
morphism has been associated with altered distribution and
behaviour of a number of pharmaceuticals which are ligands for
P-gp efﬂux, but studies on more SAE patients are required to con-
ﬁrm whether an association between mdr1 polymorphism, altered
levels of IVM reaching the brain and L. loa microﬁlarial burdens in
the brain are involved in IVM SAEs in humans.
Moxidectin has undergone phase I and phase II evaluation in
humans and is slated for phase III evaluation (Bockarie and Deb,
2010). There have been no reports of severe adverse events after
MOX treatment in humans (http://www.apps.who.int/tdr/svc/pub-
lications/tdr-research-publications/moxidectin). However, care
has been taken to not expose individuals with loaiasis to MOX in
these studies. Based on the lower CNS toxicity in dogs and mice fol-
lowing MOX exposure, compared with IVM toxicity, and different
effects of mdr1ab knockout in mice on accumulation of MOX in
the brain compared with IVM, MOX could be less likely to precip-
itate SAEs in people under treatment. Nevertheless, despite these
theoretical possibilities, this will not be conﬁrmed until more
experience has been gained with using MOX in humans and until
a better understanding of IVM SAEs is realised. However, if further
studies conﬁrm an association between mdr1 polymorphism, bur-
den of L. loa microﬁlaraemia and IVM SAEs, MOX may prove safer
for use in these humans than IVM because it is less dependent on
the integrity of blood–brain barrier P-gp for maintaining non-toxic
levels in the brain and thus for CNS safety.
8.4. Ecotoxicology of avermectins and moxidectin
The world wide use of MLs and their broad-spectrum of activity,
including against some arthropods, have raised the issue of the
environmental consequences of ML-based treatments for non-tar-
get organisms. The problem of ecotoxicology of MLs relies on the
primarily excretion of MLs, in the faeces, with noticeable insecti-
cidal activity on non-target organisms. Thus, dung beetles which
are essential for recycling of dung are exposed to signiﬁcant
amounts of drug that may impair their positive contribution to
the ecosystem. Alarm was raised when a ﬁeld trial reported that
faeces of calves ﬁtted with intra-ruminal slow-release IVM boluses
failed to degrade in the normal way and this failure was associated
with the absence of dung-degrading insects (Wall and Strong,
1987). Since it releases drug over 135 days, the intra-ruminal
slow-release IVM bolus formulation has been successfully mar-
keted to treat cattle and ensure protection against reinfestation
in the ﬁeld. Based on the almost complete excretion of the parental
IVM in the faeces, and the high dose provided, a large amount of
IVM is found in dung during and following the period of protection
(Alvinerie et al., 1999b). The dramatic impact on dung fauna re-
sulted in this long-acting IVM formulation being retired from some
markets in 2004.
Since then, several exhaustive reviews summarised the impact
of anthelmintics on non-target fauna (Lumaret and Errouissi,
2002) with the most recent review reporting the inﬂuence of
MLs on the terrestrial and aquatic environment and their living
organisms (Lumaret et al., 2011). This section draws extensively
on these reports.
Information on the impact on the environment of IVM and
other avermectins has been compiled for drug registration.
Avermectin residues in animal faeces, at amounts generated byadministration of a standard dose, affect arthropod development
by causing mortality and many sublethal effects on adults and
larvae of several species of Diptera and Coleoptera (Steel and
Wardhaugh, 2002). The potential ecotoxicity of MOX has also
been studied. From many studies comparing the effects of differ-
ent MLs on dung fauna, it appears clearly that MOX is much less
toxic that the avermectins against different developmental stages
and adult arthropods. Several studies showed a reduction in the
number of ﬂies and other organisms in dung after treatment of
cattle with MOX without any delay in the degradation of dung
(Lumaret and Errouissi, 2002). It was concluded that MOX was
ecologically safer than IVM (Herd, 1995). In cattle, a dose rate
of 0.2 mg/kg IVM is toxic to dung beetles feeding on the faeces,
while MOX had no adverse effects on adult dung beetles (Fincher
and Wang, 1992). Similar conclusions have been reported with
treated sheep (Wardhaugh et al., 1993) and horses (Lumaret
and Errouissi, 2002). More speciﬁcally, major differences between
IVM and MOX effects have been shown in experimental tests
with the dung beetle, Aphodius constans. IVM was the more toxic
substance against larvae with a LC50 of 0.88–0.98 mg per kg of
dung dry weight versus a MOX LC50 of 4–5 mg per kg of dung
dry weight (Hempel et al., 2006). Another study performed in
Argentina followed the survival of dung beetles after DRM or
MOX administration in cattle, at therapeutic dose rates of
0.2 mg/kg (Suarez et al., 2009). The number of living insects
recovered at days 3, 11 and 21 post-treatment from the control
pats was signiﬁcantly higher than those from the treated-animal
pats, conﬁrming the insecticidal activity of both MLs. However, a
lower adverse effect was observed for MOX as more insects were
recovered in the dung of animals receiving MOX treatments than
those receiving DRM. Faecal residues of both drugs presented a
similar pattern of chemical degradation after environmental
exposure of the dung, revealing that the differential non-target
toxicity effects between the two drugs was not due to different
drug degradation kinetics.
This lower toxicity of MOX against dung fauna when compared
with IVM and other avermectins is in full agreement with the low-
er efﬁcacy of MOX reported against other insects such as the
Anophelesmosquito (Butters et al., 2012) (see Section 5). The mech-
anism underlying these differences remains to be clariﬁed. It may
be linked to a lower afﬁnity of MOX for the insect ligand-gated ion
channel receptors or to the avermectins and MOX not targeting the
same subset of receptors. In the same vein, these data may parallel
those of Ardelli et al. (2009) who showed that IVM inhibited pha-
ryngeal pumping in C. elegans with a 64-fold greater potency than
did MOX (see Pharmacodynamics section). These observations sug-
gest that the use of MOX rather than avermectins in long-acting
formulations, that release drug for a long period of time, would
be less ecotoxic.9. Interaction of avermectins and moxidectin with ABC
transporters in nematodes
9.1. Nematode ABC transporters
IVM and other MLs are known to select P-gp and other ABC
transporter genes in nematodes such as H. contortus and O. volvulus
(see discussions below on modulation of expression and resistance
mechanisms). A recent study performed on H. contortus eggs to
study nematode P-gp (or other multidrug ABC transporters) has re-
ported effects of different MLs (Kerboeuf and Guegnard, 2011) on
the inhibition of rhodamine 123 transport. In this model, no direct
transport of the anthelmintics was shown, but rhodamine 123 was
clearly actively transported. Given that rhodamine 123 is a refer-
ence substrate for mammalian P-gp and other multidrug ABC
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porters in H. contortus eggs. MLs, which inhibit P-gp-mediated ef-
ﬂux in mammals, activated the efﬂux of rhodamine 123 in this
nematode model. The inducing activities, reﬂected by the EC50 val-
ues, differed signiﬁcantly between the MLs. IVM had no signiﬁcant
effect, followed by ABM, MOX, EPM, DRM, EMM and SLM (greatest
effect). The presence of a double bond at C22–23 correlated with
higher inducing activity (ABM > IVM), as did the presence of the
cyclohexyl group at C25 (SLM > all other MLs; DRM > ABM). This
work suggests that the mechanism of transport, mediated through
MDR transporters, may differ between nematodes and mammals.
But it also provides information on the differential interactions of
the various MLs with nematode transporters which can be related
to their different structures.
More recently, preliminary data on the direct interaction of a
nematode transporter with xenobiotics were determined using a
model of heterologous expression of H. contortus P-gp 2 (Hco-Pgp
2) in mammalian cells. This transporter was able to efﬂux rhoda-
mine 123 and this efﬂux was inhibited by valspodar, IVM and
MOX (Godoy and Prichard, personal communication). As observed
with mammalian P-gp, MOX was markedly less potent in inhibit-
ing P-gp transport activity which conﬁrms that the structure of
the drug is also important for its interaction with the nematode
P-gp. However, it is clear that the nematode P-gp differs signiﬁ-
cantly from mammalian MDR1 (P-gp) in the nature of the MOX
inhibition of rhodamine transport and further investigations need
to be performed in order to describe the precise interaction of dif-
ferent avermectins and MOX with nematode P-gps, MRPs and half-
transporters.9.2. Avermectins and moxidectin modulate the expression of efﬂux
transporters in nematodes and invertebrates
Modulation of P-gp expression and that of other related mul-
tidrug transporters has been reported under ML pressure in many
organisms including nematodes and it is considered to be a
molecular mechanism for avermectin-resistance. In parasitic
nematodes, multidrug ABC transporter homologue genes are se-
lected under IVM pressure (Prichard, 2007; Lespine et al., 2012)
and several were shown to be overexpressed in IVM-resistant
worms such as H. contortus (Xu et al., 1998) and C. elegans (James
and Davey, 2009). Recently, Dicker et al. (2011) and Williamson
and Wolstenholme (2012) have shown signiﬁcant constitutive
upregulation of some P-gps in IVM-resistant H. contortus and T.
circumcincta, while the feeding of multidrug resistance reversing
chemicals to IVM-resistant larvae of H. contortus and T. circum-
cincta in vitro, reversed the resistance (Bartley et al., 2009). Prich-
ard and Roulet (2007) reported that IVM, and to a lesser extent
MOX, upregulated the expression of several P-gps in H. contortus.
In the cattle tick Rhipicephalus (Boophilus) microplus (Acari Ixo-
dide), a gene sequence identiﬁed as an ABC transporter was sig-
niﬁcantly up-regulated in IVM-resistant females suggesting that
such overexpression contributes to IVM detoxiﬁcation in this
arthropod (Pohl et al., 2011). It is noteworthy to mention that
such induction was also reported after exposure to the avermec-
tin emamectin in the marine parasitic sea lice Lepeophtheirus sal-
moni (Tribble et al., 2007).10. Resistance
10.1. Resistance to avermectins and to moxidectin in the ﬁeld
Resistance to IVM was ﬁrst reported within 3 years of its com-
mercial launch (Carmichael et al., 1987). Resistance to the aver-
mectins has developed in many nematode parasites of animals,while resistance to MOX is increasing (Sutherland and Leathwick,
2011; Kaplan, 2004; Wolstenholme et al., 2004; Craig, 2006;
Pomroy, 2006; Prichard, 2007; Geary et al., 2011; Sargison,
2011). IVM resistance has also been found in human O. volvulus
(Osei-Atweneboana et al., 2011). In this review, we have not at-
tempted to catalogue all of the reports of avermectin resistance
or MOX resistance. A summary of all of the known literature in
which a comparison has been made between an avermectin (usu-
ally IVM) and MOX in the same isolate or the same study, as well
as the result, location of the isolate/study and the reference may
be found in Supplementary Table S1. More details on each indi-
vidual study can be found in the references to that table. At rec-
ommended dose rates, resistance to avermectins in H. contortus is
very widespread, and resistance to MOX occurs, but is less wide-
spread. Avermectin resistance is also increasing alarmingly in T.
circumcincta, particularly in New Zealand and UK. MOX resistance
in T. circumcincta occurs, but is still relatively rare. Avermectin
resistance in T. colubriformis is still relatively rare, but it has been
reported in Australia (Le Jambre et al., 2005), New Zealand, Italy
and Brazil (see Supplementary Table S1), and MOX resistance, still
less common, has been found in this species in Australia (Le Jam-
bre et al., 2005) and Brazil (Almeida et al., 2010). Resistance to
avermectins and to MOX is also becoming common in Cooperia
spp., especially C. oncophora in cattle around the world, although
usually MOX remains more effective than the avermectins once
resistance is detected. Avermectin resistance also occurs in H. pla-
cei (and H. contortus) in cattle. There are few reports of MOX
resistance in Haemonchus spp. in cattle. IVM resistance has been
found in O. ostertagi L4 larvae, but not so far to MOX. There is
preliminary evidence of possible resistance to a number of aver-
mectins, and to MOX in lungworm in cattle in Brazil (Molento
et al., 2006). In horses, resistance to both IVM and MOX was ﬁrst
detected in Parascaris equorum (Boersema et al., 2002). IVM resis-
tance has arisen only recently in small strongyles in horses, while
MOX still seems to be effective against these species (Milillo
et al., 2009; Traversa et al., 2009) (Supplementary Table S1).
IVM and MOX resistances have been detected in nematode para-
sites of llama and alpaca (Gillespie et al., 2010). Recently, there
has been growing evidence that resistance to heartworm preven-
tatives is developing in USA (see Geary et al., 2011). In a recent
study comparing all of the heartworm preventative ML molecules
at their recommended dose rates against one strain of D. immitis,
low numbers of infective larvae were able to establish in dogs
receiving IVM, SLM or milbemycin oxime, but MOX remained
100% effective (Blagburn et al., 2011). Another study (Snyder
et al., 2010) also found that IVM and MO did not completely pre-
vent D. immitis establishment with the same strain of heartworm.
Resistance to avermectins is known in ectoparasites of animals
and arthropod pests of crops (Clark et al., 1995; Humeres and
Morse, 2005) and IVM resistance in human Sarcoptes scabiei has
been reported (Currie et al., 2004).
A full understanding of the mechanisms and genetics of aver-
mectin and MOX resistances is still lacking, however, these types
of resistance appear to be multigenic (Prichard, 2001; McCavera
et al., 2007). Some early studies suggested that avermectin and
MOX resistances may be the same (Conder et al., 1993; Shoop,
1993; Shoop et al., 1993, 1995). These authors conducted assays
against IVM resistant H. contortus in model host systems, at dose
rates below those recommended for livestock, and found shifts in
responses to both IVM and MOX compared with IVM susceptible
laboratory strains. The expression of resistance is affected by phar-
maceutical dose rate and low dose rates can be used to search for
possible developing resistance which can foreshadow future resis-
tance to the normal use dose rate. However, both the early and
more recent experience with avermectin resistance and MOX resis-
tance, and the measured efﬁcacy in the ﬁeld, indicate that while
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and MOX, at its recommended dose rate MOX is more effective, of-
ten still highly effective, than an avermectin assayed at the same
time against the same isolates of nematodes in sheep, goats, cattle,
horses, and dogs (Supplementary Table S1). Le Jambre et al. (2005)
found that the mode of inheritance of resistance to MOX and ABM,
in H. contortus, was different and concluded that ‘‘it should be
made clear whether it is resistance to the avermectins (IVM resis-
tance) or resistance to the milbemycins (MOX resistance) that is
being described.’’
A report by Rendell et al. (2006) suggested that the use of
MOX led to a higher frequency of ML resistance in T. circumcincta
than did use of IVM (or ABM) in sheep farms in South-eastern
Australia. The conclusions were based on records of the previous
5 years, and in some cases 10 years, of anthelmintic treatments
and an assessment of ML resistance based on FECRT results fol-
lowing treatment with a half-dose rate of IVM (0.1 mg/kg) and
a cut-off of <95% efﬁcacy for a declaration of ML resistance. A
careful analysis of the paper makes it difﬁcult to conclude that
either IVM or MOX repeated treatments more rapidly selects for
avermectin (or MOX) resistance for the following reasons.
Although the study looked at a 5–10 year history of anthelmintic
use, in fact only 6 properties had used exclusively MOX in the
5 years prior to the study and of these 4 had resistance to the
half-dose IVM (none were reported as resistant to MOX), and 2
were still susceptible to IVM. Meanwhile, there were only 2 prop-
erties that had used an avermectin exclusively for the previous
5 years and both were resistant to the half-dose IVM. Of the
103 properties investigated 49.5% had T. circumcincta that were
resistant to the half-dose IVM. There was no evidence presented,
or any claim, of any MOX resistance on any property, even though
the study spoke of ML-resistance based on FECRT to the half-dose
IVM. Finally, properties using MOX are quite likely to have chan-
ged from using an avermectin because IVM resistance had re-
sulted in treatments with avermectins not producing the level
of parasite control that was desired. This would of course be hard
to assess, but information on farmer perceptions of possible resis-
tance was not presented from the questionnaire survey that was
conducted. Thus, the study was possibly biased by the properties
that used MOX having an existing level of avermectin resistance.
As 49.5% of the properties were found to have a measure of IVM
resistance and no MOX resistance was reported, despite its use
over several years, the study does suggest that avermectin resis-
tance may be easier to select, using avermectins, or possibly
MOX, than actual MOX resistance. This conclusion is supported
by the controlled selection study of Ranjan et al. (2002) who sub-
jected an anthelmintic susceptible isolate of H. contortus to selec-
tion by either IVM or MOX, 28 days after infection of sheep, at
dose rates that produced 85–95% reduction in faecal egg count,
over 22 generations. After the 22 generations of selection, the
H. contortus selected by either IVM or MOX were resistant to
0.2 mg/kg IVM (IVM efﬁcacies of selected strains of 70% and
88%, respectively), whereas following selection with either IVM
or MOX, both strains were highly susceptible to MOX, even at a
reduced dose rate of 0.05 mg/kg (>99% efﬁcacy in both strains).
The data in this study support a conclusion that there is some de-
gree of selection by both IVM and MOX for avermectin resistance,
but also is consistent with a conclusion that additional factors
(genes/mechanisms) are required before MOX resistance shows
to its recommended dose rate, compared with avermectin resis-
tance. In this review, we have compared what is known about
the avermectins (usually IVM), and MOX as a speciﬁc type of
ML. What is known about the mechanisms of avermectin and
MOX resistances and possible reasons why avermectin resistance
and MOX resistance share some similarities, but are not identical,
are brieﬂy discussed below.10.2. Resistance mechanisms for avermectin and moxidectin
resistances
Evidence for the involvement of chloride channel receptors in
avermectin-resistance in parasitic nematodes is limited, although
extensive investigations have been conducted to look for such an
explanation of avermectin-resistance. In C. elegans, the deletion
of the three GluCl genes avr-14, avr-15 and glc-1 (Dent et al.,
2000) causes a marked decrease in sensitivity of this nematode
to IVM, showing that the products of these GluCl genes are in-
volved with the sensitivity of C. elegans to IVM. The gene GluCla,
an avr-14 homologue, has been shown to be under selection pres-
sure in IVM resistant strains of H. contortus that had been under
IVM or MOX selection (Blackhall et al., 1998), but no speciﬁc resis-
tance-associated sequence changes were identiﬁed. The most con-
vincing evidence that a sequence change in a GluCl may cause IVM
resistance comes from studies with the cattle parasite, C. oncopho-
ra. Njue and Prichard (2004) showed that an avr-14 homologue
was under selection in an IVM-resistant ﬁeld isolate and subse-
quently, Njue et al. (2004) showed that a L256F change in the Glu-
Cla3 caused a threefold loss of sensitivity to IVM and MOX. Using
site-directedmutagenesis to introduce the L256Fmutation into the
H. contortus GluCla3B (avr-14B homologue) subunit, McCavera
et al. (2007) found the mutation reduced IVM afﬁnity by 6.5-fold.
However, to date the L256F SNP has only been found naturally in
one ﬁeld isolate of C. oncophora despite investigations of many
IVM resistant isolates. Recently, a decrease in polymorphism and
in level of expression of the avr-14B homologue has been reported
in IVM resistant C. oncophora and O. ostertagi, suggesting a possible
link of this gene with IVM resistance (El-Abdellati et al., 2011).
These authors and Williamson et al. (2012) found a slight reduc-
tion in expression of two other GluCls, Hco-glc-3 and Hco-glc-5 in
an isolate of IVM resistant H. contortus. It is of interest that a nat-
urally avermectin resistant strain of C. elegans, CB4856, showed
signiﬁcant genetic diversity in the glc-1 gene, compared with the
wild-type N2 Bristol strain. This GluCl based resistance appeared
to be recessive and was associated with a general ﬁtness deﬁcit,
which appeared to be maintained by a balanced selection between
general ﬁtness and resistance to pathogenic bacteria producing
avermectins (Ghosh et al., 2012).
A possible involvement in IVM resistance of the putative GABA-
gated chloride channel subunit HG1 has been reported in H. contor-
tus (Blackhall et al., 2003). It was co-expressed with the C. elegans
GAB-1 subunit in Xenopus oocytes to form a functional IVM-sensi-
tive GABA-gated chloride channel. When two different alleles iden-
tiﬁed from the Blackhall study (A: wild type and E: IVM selected)
were co-expressed with GAB-1, 10 lM IVM, when co-applied with
10 lM GABA, potentiated the current of the HG1A/GAB-1 (sensi-
tive) receptor, but attenuated the GABA response of the HG1E/
GAB-1 (resistant) receptor (Feng et al., 2002). However, more data
are needed on whether the effects are likely to occur at pharmaco-
logically relevant IVM concentrations in vivo to conclude an
involvement with IVM resistance. The large diversity of ligand-
gated chloride channels in nematodes and the different effects that
IVM and MOX have on nematodes and on expression of ligand-
gated chloride channels, raise the strong possibility thatwhile some
ligand-gated chloride channels may be affected to a similar extent
by both avermectins and MOX, not all of the ligand-gated chloride
channels will respond similarly to both avermectins and MOX and
be under the same selection in nematodes that are avermectin
resistant compared to those that are selected with MOX.
There is considerable body of evidence that IVM and other MLs
select on nematode P-gps and other ABC transporters (Lespine
et al., 2012), suggesting their involvement in avermectin resistance
mechanisms. Nematodes have a large and diverse number of ABC
transporters which may be involved with either avermectin or
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volved to the same extent with each type of ML. In addition to pos-
sible ligand-gated chloride channel receptors and ABC transporters,
other, yet to be identiﬁed genes andmechanismsmay be important
for either avermectin resistance or MOX resistance. The complexity
of the putative mechanisms and number of possible genes involved
in avermectin or MOX resistance leave very large possibilities
which could explain the differences in the expression of resistance
between the avermectins and MOX. Evidence for the involvement
of P-gps, or other MDR transporters, in ML resistance in nematodes
is indicated by the capacity of typical P-gp inhibitors to increase the
efﬁcacy of IVM in susceptible worms or to reverse resistance in
resistant strains. Indeed, the in vitro susceptibility to IVM of both
sensitive and resistant isolates of T. circumcincta and H. contortus
was increased (Bartley et al., 2009) by valspodar, verapamil and
pluronic acid, a surfactant polyol; compounds which have been
shown to inhibit mammalian P-gp and to reverse multidrug resis-
tance in mammalian cells. Similarly, studies performed on IVM-
resistant C. elegans strains showed thatmultidrug resistance revers-
ing agents, verapamil and PSC833 (valspodar), were able to restore
IVM sensitivity even in a highly resistant strain. Similarly, the MRP
inhibitors, MK571 and buthionine sulfoxamine also reversed resis-
tance. Thus, ABC transport proteins appear to be involved in the
development of IVM resistance in C. elegans which is in agreement
with the increased expression of P-gp and MRP genes in IVM-resis-
tant strains (James and Davey, 2009). In addition, differential re-
sponse was observed with MOX when compared with IVM in one
of the two C. elegans strains which had been selected under IVM
pressure. The worms resistant to 6 ng/ml IVM (>6-fold resistance)
showed low cross-resistance to MOX (1.5-fold). The strain which
was resistant to 10 ng/ml IVM (19-fold) was highly resistant to
MOX (35-fold), levamisole (5.2-fold), and pyrantel (4.9-fold). These
data suggest an involvement of ABC transporters in IVM resistance
and that those transporter-based resistance mechanisms can lead
to multidrug resistance.11. Future prospects and conclusions
These ﬁndings have important biological consequences, consid-
ering that if the differences in structure lead to different pharma-
cokinetic and pharmacodynamic behaviour, they could also have
an impact on their toxicity, efﬁcacy, the emergence of resistance,
and the extent of cross-resistance. A better understanding of the
interaction between avermectins, or MOX, with transporters and
ligand-gated ion channels may help to improve the current ML-
based chemotherapy. This is desirable in order to sustain the efﬁ-
cacy of this broad-spectrum class of endectocides in the context
of worsening resistance that threatens to severely limit current
parasite control strategies.
Where a major component of a multigenic resistance is due to
altered expression or activity of ABC transporters in resistant iso-
lates, it is feasible to consider pharmacologically reversing that
resistance with MDR reversing agents and so remove the advan-
tage that genetically resistant strains enjoy in the presence of the
anthelmintic to which they are resistant. Furthermore, when efﬂux
based mechanisms are key components of resistance, it may be
possible to screen for new ML entities which are not, or are less
susceptible to transporter based resistance. Similarly, a better
understanding of the similarities and differences in the interaction
of different avermectins and milbemycins with ligand-gated ion
channels in parasites would be useful for optimising parasiticide-
receptor interactions and possibly extending the spectra and effec-
tiveness of the MLs, or help in the discovery of other chemical
structures with antiparasitic activity.In the face of increasing anthelmintic resistance, combinations
of MLs with other anthelmintics are increasingly being advocated
(Leathwick and Hosking, 2009). Improving our knowledge of the
differences and similarities of MOX and the avermectins can be
important, for numerous reasons, when pharmaceutical combina-
tions are being considered. As discussed above, because MOX and
the avermectins have different effects on multidrug ABC transport-
ers, a combination of a non-ML anthelmintic with an avermectin or
MOX can bring different advantages or disadvantages to efforts to
delay the selection for resistance. Furthermore, because a potent
ABC transport ligand, such as IVM, can alter the pharmacokinetics,
in the host and/or in the parasite of another anthelmintic, consider-
ation of the pharmacological consequences of combination, in
terms of anti-parasite efﬁcacy and potential host toxicity, should
be consideredwhen different anthelmintics are combined to broad-
en the spectrum of activity and convenience of administration.
Better understandings of the factors which can lead to host tox-
icity are also important. The available data with IVM-sensitive dogs
and P-gp deﬁcient mice indicate that MOX is much less dependent
on normally functioning blood–brain barrier transporters to regu-
late drug entry into/efﬂux from the CNS than are the avermectins.
Further investigations into these differential effects will be impor-
tant for improving antiparasite safety in dogs and probably other
host species. In fact, this could also be critically important for
avoiding possible severe adverse events in humans which have
led to mortalities in some individuals heavily infected with L. loa,
and which has led to a failure to implement onchocerciasis and
lymphatic ﬁlariasis control in some regions of Africa.
There are other potential beneﬁts from obtaining a better
understanding of the similarities and differences between the
avermectins and MOX, including possible decisions about which
MLs are most suitable and safest, from the point of view of ecotox-
icity and resistance selection, for development in long-acting for-
mulations or high dose rate broad-spectrum formulations. The
avermectins and milbemycins are remarkable pharmaceuticals
and a better understanding of their speciﬁc properties in biological
systems is likely to reveal new uses and new products from these
families in the future.
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